Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026–2030: Emerging Trends and Forecast Opportunities
Uncover key drivers, emerging technologies, and competitive movements shaping the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has experienced robust expansion in recent years. This market is projected to increase from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. The historical growth of the market is primarily due to factors such as the increasing prevalence of chronic pancreatitis, a rising awareness concerning digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the growth in home healthcare services.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is projected to experience robust expansion in the coming years. This market is anticipated to reach $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth during the forecast period include progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening scope of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends shaping the forecast period encompass advanced pancreatic enzyme replacement therapies, point-of-care diagnostic solutions, tailored nutritional management programs, non-invasive imaging methods for epi, and the integration of telehealth into epi management.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Drivers Are Supporting Technological Adoption In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The growing population affected by diabetes is projected to stimulate the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is defined as a long-term metabolic ailment marked by sustained elevated blood sugar levels (hyperglycemia), arising from the body’s failure to produce sufficient insulin or utilize it effectively. Exocrine pancreatic insufficiency (EPI) therapy, which includes pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption for individuals with both diabetes and EPI, and also aid in better glycemic control for diabetic patients. As an illustration, in June 2024, The National Health Service (NHS England), a UK public healthcare system, reported that the number of people identified with pre-diabetes in England climbed to 3,615,330 in 2023, representing an 18% rise from 3,065,825 in 2022. Furthermore, for those under 40, cases increased by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising incidence of diabetes among the populace is propelling the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Which Segments Are Contributing To The Growth Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
What Trends Are Driving The Growth Trajectory Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Leading firms within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly employing strategic partnerships to boost technological integration and broaden their market presence. Such partnerships involve cooperative arrangements between multiple entities, pooling their collective resources, knowledge, and endeavors to attain shared aims. An illustrative example occurred in February 2023, when Codexis, Inc., a US-based protein engineering firm, and Nestlé Health Science, a nutrition science company based in Switzerland, disclosed preliminary outcomes from their Phase 1 clinical trial for CDX-7108, an experimental treatment designed for exocrine pancreatic insufficiency (EPI). These Phase 1 trial results create opportunities for subsequent research that holds the potential to substantially enhance treatment alternatives for individuals afflicted with EPI.
Who Are The Core Companies Influencing Trends In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In The Coming Years?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026
Exocrine Pancreatic Insufficiency Market Report 2026
Acute Pancreatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
